Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the addison’s disease market?

The market for Addison’s disease has seen a swift expansion in recent years. It is predicted to surge from $2.05 billion in 2024 to $2.25 billion in 2025, with a compound annual growth rate (CAGR) of 10.0%. The historic period’s expansion can be linked to a global increase in Addison’s disease cases, heightened awareness concerning adrenal insufficiency, a rise in healthcare spending, more recorded cases of autoimmune diseases, and an upsurge in the geriatric population.

What will be the addison’s disease market size in the future?

The market size for Addison’s disease is projected to experience significant expansion in the upcoming years, escalating to a value of $3.26 billion by 2029 with a compound annual growth rate (CAGR) of 9.7%. The predicted growth during the forecast period is due to factors such as heightened demand for cutting-edge therapeutics, increased emphasis on early detection, a rise in cases of congenital adrenal hyperplasia, the expansion of telemedicine services, and a growing number of adrenal tuberculosis instances. Major advancements in the forecast period include progress in laboratory test methodologies, innovations in hormone replacement therapies, development in imaging technology, the evolution of long-lasting injectable remedies, and the incorporation of artificial intelligence in diagnostic instruments.

Get your addison’s disease market report here!

https://www.thebusinessresearchcompany.com/report/addisons-disease-global-market-report

What main drivers are fueling expansion in the addison’s disease market?

The rise in the incidence of autoimmune diseases is anticipated to boost the expansion of the Addison’s disease market. Autoimmune diseases result when the immune system erroneously targets the body’s own healthy tissues, leading to inflammation and harm. Factors such as genetic predispositions, environmental contaminants and dietary modifications, as well as lifestyle factors including stress and insufficient physical activity, are all contributing to the escalating occurrence of autoimmune diseases. The rising incidence of autoimmune diseases heightens the probability of concurrent diagnosis with Addison’s disease, as numerous patients incur additional autoimmune disorders. For example, Versorgungsatlas.de, a company based in Germany, stated in November 2024 that in 2022, out of 73,241,305 insured persons, 6,304,340 were identified with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. This prevalence rate outstrips earlier approximations of 3% to 9%. Consequently, the rising incidence of autoimmune diseases is stimulating the growth of the Addison’s disease market.

What key areas define the segmentation of the global addison’s disease market?

The addison’s disease market covered in this report is segmented –

1) By Type: Primary Adrenal Insufficiency, Secondary Adrenal Insufficiency, Tertiary Adrenal Insufficiency

2) By Drug Class: Oral Corticosteroid, Hydrocortisone, Fludrocortisone, Corticosteroid Injections

3) By Diagnosis: Laboratory Testing, Imaging Testing

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Primary Adrenal Insufficiency: Autoimmune Addison’s Disease, Infectious Addison’s Disease, Other causes of primary adrenal insufficiency

2) By Secondary Adrenal Insufficiency: Pituitary gland dysfunction, Hypothalamic dysfunction

3) By Tertiary Adrenal Insufficiency: Hypothalamic or pituitary suppression due to long-term steroid use, Other causes of tertiary adrenal insufficiency

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21084&type=smp

Who are the dominant players expanding their reach in the addison’s disease market?

Major companies operating in the addison’s disease market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz, Ipsen S.A., Neurocrine Biosciences Inc., Recipharm AB, Accord Healthcare, Eton Pharmaceuticals, DuoCort Pharma, Diurnal Group plc, Roxane Laboratories Inc.

What key trends are currently impacting the addison’s disease market’s development?

Leading corporations in the addison’s disease market are prioritizing innovation strategies like regenerative therapies. These methods are intended to improve treatment possibilities, enhance patient results, and potentially lessen the life-long reliance on hormone replacement treatments by encouraging the body’s natural adrenal activity. Regenerative therapies are medical strategies focused on replacing or regenerating cells, tissues, or organs in humans to restore their normal functioning and encourage healing in situations of injury, illness, or deterioration. For example, in July 2024, Eton Pharmaceuticals, Inc., an American public pharmaceutical firm specializing in the development and commercialization of novel treatments for rare diseases, announced the FDA’s approval of its New Drug Application (NDA) for ET-400, a unique hydrocortisone oral solution formulation. ET-400 is more convenient to store and transport than other variants that might need cold storage. The liquid format caters to the needs of young patients who might find it challenging to swallow conventional tablets by providing precise dosage.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21084

Which regions are emerging as leaders in the addison’s disease market?

North America was the largest region in the addison’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the addison’s disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Fibromyalgia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report

Pharyngitis Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharyngitis-treatment-global-market-report

Bleeding Disorders Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: